# To Evaluate the Efficacy and Safety of the Transfemoral Mitral Valve Repair System in the Treatment of Patients With Moderately Severe and Severe Functional Mitral Regurgitation(FMR) Who Remained Clinically Symptomatic After Guideline-directed Medical Treatment

Study · id `cardio:ct-nct05508438` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05508438](<https://clinicaltrials.gov/study/NCT05508438>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05508438

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 140 participants.

## Technical summary

Registry record NCT05508438. Allocation not applicable; no masking; primary purpose treatment. Start 2022-08-30 (anticipated); primary completion 2023-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 140 participants (planned count; ClinicalTrials.gov record NCT05508438, source copy `cardio:ctgov-nct05508438-2022-08-19`, retrieved 2026-10-26)
- Planned start: 2022-08-30 (anticipated) (ClinicalTrials.gov record NCT05508438, source copy `cardio:ctgov-nct05508438-2022-08-19`, retrieved 2026-10-26)
- Primary completion: 2023-12-30 (anticipated) (ClinicalTrials.gov record NCT05508438, source copy `cardio:ctgov-nct05508438-2022-08-19`, retrieved 2026-10-26)
- Completion: 2027-12-30 (anticipated) (ClinicalTrials.gov record NCT05508438, source copy `cardio:ctgov-nct05508438-2022-08-19`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05508438, source copy `cardio:ctgov-nct05508438-2022-08-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05508438-2022-08-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: To Evaluate the Efficacy and Safety of the Transfemoral Mitral Valve Repair System in the Treatment of Patients With Moderately Severe and Severe Functional Mitral Regurgitation(FMR) Who Remained Clinically Symptomatic After Guideline-directed Medical Treatment
- Condition: Mitral Valve Insufficiency
- Intervention (Device): Transfemoral mitral-valve repair
- Lead sponsor: Pan Xiangbin
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Mitral regurgitation (`cardio:mitral-regurgitation`)

## Provenance

Content hash: e5b2a5609aaaa5533fd72d9a889e6f92410ff538f1b3ed132ffa9ad2c31765ee
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
